N Engl J Med. 2023;388(1):33–43

Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS

Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer

Background: KRAS p.G12C mutation occurs in approximately 1–2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.
Methods: The authors conducted a single-group, phase 1–2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C-mutated pancreatic cancer who had received at least 1 previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival (PFS), and overall survival (OS). Safety was also assessed.
Results: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1–8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI]: 10–37). The median PFS was 4.0 months (95% CI: 2.8–5.6), and the median OS was 6.9 months (95% CI: 5.0–9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation.

Conclusions: Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous treatment.

D.S. Hong, M.D., Investigational Cancer Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,

DOI: DOI: 10.1056/nejmoa2208470

Back to overview

this could be of interest:

Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts

Gastroenterology. 2023;164(1):117–33.e7

Post-pancreatitis diabetes mellitus is common in chronic pancreatitis and is associated with adverse outcomes

United European Gastroenterol J. 2023;11(1):79–91

More articles on the topic